EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information

Khashayar Dashtipour, Han S Lee iD, Aaron Ellenbogen, Rashid Kazerooni iD, Todd M Gross iD, David A Hollander, Conor J Gallagher iD

Toxins · 2024

DOI: 10.3390/toxins16100442 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxins, 2024. Verfasst von Khashayar Dashtipour und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology/Movement Disorders, Loma Linda University, Loma Linda, CA 92354, USA. Hauptthemen laut MEDLINE: Torticollis, Muscle Weakness, Botulinum Toxins, Type A, Deglutition Disorders. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Revance Therapeutics, Revance Therapeutics, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The first-line management of cervical dystonia (CD) symptoms is intramuscular injection of botulinum toxin type A (BoNTA). However, a comparison of safety among BoNTAs is difficult because, per regulatory authorities, units of BoNTA activity are not interchangeable. Dysphagia and muscle weakness are widely considered two key adverse events to monitor closely in the treatment of CD. This integrated analysis compared the safety of BoNTAs approved for CD in the US by evaluating relationships between the incidence of dysphagia and muscle weakness in prescribing information and the core neurotoxin content. Coefficients The coefficients of determination (R2) and trendlines were estimated via regression-based lines of best fit. Adverse drug reaction (ADR) rates were strongly correlated with core neurotoxin amounts for conventional BoNTAs (slope coefficients: dysphagia = 0.048, R2 = 0.74; muscle weakness = 0.096, R2 = 0.82). The published ADR rates at approved doses for conventional BoNTAs were higher compared with DaxibotulinumtoxinA (DAXI; DAXXIFY®, Revance Therapeutics, Inc., Nashville, TN, USA) by core neurotoxin content. The use of a core neurotoxin amount was found to be an effective method for comparing the safety of BoNTA products. Current clinical trials suggest that DAXI, a novel BoNTA formulation, provides a potentially wider safety margin compared with other approved BoNTAs for CD. The lower amount of core neurotoxin administered at approved doses compared with conventional BoNTAs may explain low on-target ADRs like muscle weakness, whereas reduced diffusion from the injection site is thought to be responsible for low off-target ADRs like dysphagia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TorticollisMuscle WeaknessBotulinum Toxins, Type ADeglutition DisordersNeuromuscular AgentsHumans

Stichwörter der Autor:innen

botulinum toxinscervical dystoniadysphagiadystonic disordersmovement disordersmuscle weaknessneuromodulatorpeptidestype A

Substanzen

Botulinum Toxins, Type ANeuromuscular Agents

Autor:innen und Institutionen

  • Department of Neurology/Movement Disorders, Loma Linda University, Loma Linda, CA 92354, USA.
  • Department of Neurology, The Permanente Medical Group, Greater Southern Alameda Area-San Leandro/Fremont, San Leandro, CA 94577, USA.
  • Quest Research Institute, Farmington Hills, MI 48334, USA.
  • Revance Therapeutics, Nashville, TN 37203, USA.

ORCID-Profile: Han S Lee, Rashid Kazerooni, Todd M Gross, Conor J Gallagher

Förderung

  • Revance Therapeutics
  • Revance Therapeutics, Inc.

Zitieren

APA

Dashtipour, K., Lee, H. S., Ellenbogen, A., Kazerooni, R., Gross, T. M., Hollander, D. A., & Gallagher, C. J. (2024). Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. Toxins. https://doi.org/10.3390/toxins16100442

Vancouver

Dashtipour K, Lee HS, Ellenbogen A, Kazerooni R, Gross TM, Hollander DA, et al. Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. Toxins. 2024. doi:10.3390/toxins16100442

BibTeX
@article{Dashtipour2024,
  author = {Dashtipour, Khashayar and Lee, Han S and Ellenbogen, Aaron and Kazerooni, Rashid and Gross, Todd M and Hollander, David A and Gallagher, Conor J},
  title = {Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information},
  journal = {Toxins},
  year = {2024},
  doi = {10.3390/toxins16100442}
}
Kostenlos starten →